person
Caterina P.
- Country
- Italy
- Department
- UO Ematologia I
Research Overview
assignment
37
Clinical Trials ·
- Evaluation of Acalabrutinib Monotherapy and Combination with Rituximab in Relapsed/Refractory Marginal Zone Lymphoma: A Phase 1b/2 Open-label Study
- Phase I-II Study of Romidepsin Combined with CHOEP for Initial Treatment in Young Patients with Nodal Peripheral T-Cell Lymphomas Prior to Hematopoietic Stem Cell Transplantation
- A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL (waveLINE)
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
343
Sites with multiple studies
Has run more than one trial at 343 of 544 partner sites.
Specializations
Lymphoid Malignancies
Specializes in the treatment of chronic lymphocytic leukemia (CLL) and various forms of lymphoma, with particular emphasis on novel therapeutic combinations and targeted approaches.
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Hodgkin Lymphoma
Novel Therapeutic Approaches
Focuses on investigating innovative treatment combinations incorporating targeted therapies and immunotherapy agents.
- BTK Inhibitors
- Monoclonal Antibodies
- BCL-2 Inhibitors
- Immunomodulatory Drugs
Treatment Optimization
Investigates strategies to improve outcomes in both newly diagnosed and relapsed/refractory hematologic malignancies.
- First-line Treatment Protocols
- Combination Therapies
- Treatment Response Assessment
- Personalized Medicine Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.